Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter’s Syndrome

SIMPLE SUMMARY: Patients with chronic lymphocytic leukemia who develop Richter’s Syndrome have a poor prognosis. Traditional chemo-immunotherapy approaches yield poor response rates and increase toxicity. Novel, non-myelosuppressive regimens are needed to improve outcomes and reduce toxicity. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Heyman, Benjamin M., Choi, Michael Y., Kipps, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775482/
https://www.ncbi.nlm.nih.gov/pubmed/36551520
http://dx.doi.org/10.3390/cancers14246035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775482/
https://www.ncbi.nlm.nih.gov/pubmed/36551520
http://dx.doi.org/10.3390/cancers14246035

Ejemplares similares